Effects of 2'-DI in EAE Mouse Model and MS Patient Blood Samples
In this study, 2'-DI was tested in an EAE mouse model and MS patient blood samples. It significantly reduced levels of certain immune cells related to inflammation, promoted anti-inflammatory responses, and suggested a potential to prevent MS progression in mice.
- Tags
- #MSResearch
- Most relevant to
- —
Why it matters
These findings demonstrate a promising avenue for understanding how 2'-DI might influence MS and related immune responses, potentially guiding future therapies. However, it does not establish proven clinical benefits in human subjects.
What this does not prove
This study does not establish clinical outcomes in human subjects and the effectiveness of 2'-DI in treating MS remains unproven.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Laboratory
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Yes
- Relevant MS type
- Not reported
- Publication date
- 2026-09-17
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
- Primary evidence2'-deoxyinosine ameliorates multiple sclerosis through modulating Th1/Th2 and Th17/Treg cell balance with potential involvement of AMPK phosphorylation. ↗DOI: 10.3389/fphar.2026.1837446
Supporting passages (9)
study phaseThis study was performed to investigate whether prophylactic 2'-DI intervention could prevent MS progression and elucidate its action mechanism.
study designMETHODS: 2'-DI was administered to experimental autoimmune encephalomyelitis mice in vivo and cultured peripheral blood samples from MS patients in vitro, followed by pathological analysis, body weight monitoring, and disease severity assessment.
subjectsMETHODS: 2'-DI was administered to experimental autoimmune encephalomyelitis mice in vivo and cultured peripheral blood samples from MS patients in vitro, followed by pathological analysis, body weight monitoring, and disease severity assessment.
speciesMETHODS: 2'-DI was administered to experimental autoimmune encephalomyelitis mice in vivo and cultured peripheral blood samples from MS patients in vitro, followed by pathological analysis, body weight monitoring, and disease severity assessment.
primary endpoint metProphylactic administration of 2'-DI could prevent the progression of MS and mitigate inflammatory infiltration in the EAE mouse model.
peer reviewedJournal: Frontiers in pharmacology
findings2'-DI could decrease Th1 and Th17 cells, whereas increase Treg and Th2 cells.
limitationsHowever, effective treatment for MS remains an unmet need.
publication datePublication date: 2026-09-17
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.